A single-center, cross-sectional study published in the Egyptian Rheumatology and Rehabilitation journal reports that three newly evaluated composite inflammatory indices did not demonstrate a statistically significant ability to distinguish between active and inactive disease states in patients with ankylosing spondylitis. The research, conducted by Rumeysa Samanci and Safinaz Ataoglu at Düzce University, investigated the Multi-Inflammatory Index (MII) values, specifically MII-1, MII-2, and MII-3, to determine their potential utility as complementary diagnostic tools for monitoring disease activity. The primary finding indicates that while these indices were significantly elevated in patients with ankylosing spondylitis compared to healthy controls, they failed to provide reliable differentiation based on the current level of disease activity as measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).
Ankylosing spondylitis is a chronic autoimmune rheumatic disease that primarily affects the axial joints, and objective assessment of its activity remains a significant clinical challenge. The study aimed to address this by investigating the relationship between the Multi-Inflammatory Index values and disease activity in a cohort of patients. The researchers sought to evaluate whether these composite indices, which combine traditional hemogram-based ratios with C-reactive protein (CRP) levels, could offer more objective and reliable monitoring than patient-reported outcomes alone. The investigation was designed to contribute to the expanding evidence base for assessing inflammatory markers in this specific rheumatic condition.
The study design was a single-center, cross-sectional observational study conducted at the Physical Medicine and Rehabilitation outpatient clinic of Düzce University Faculty of Medicine Research and Practice Hospital between January 2024 and October 2025. The cohort included 114 patients with ankylosing spondylitis who fulfilled the Modified New York criteria and 60 age- and sex-matched healthy controls. Patients were aged between 18 and 75 years, and those with missing data, concomitant rheumatologic diseases other than ankylosing spondylitis, or a history of severe systemic diseases were excluded. The control group consisted of healthy volunteers with no known chronic or autoimmune disease, matched to the patient group by age and sex to ensure comparability.
The Multi-Inflammatory Index values were calculated using specific formulas derived from routine complete blood count and CRP results. MII-1 was calculated as the neutrophil-to-lymphocyte ratio (NLR) multiplied by CRP, MII-2 as the platelet-to-lymphocyte ratio (PLR) multiplied by CRP, and MII-3 as the systemic immune-inflammation index (SII) multiplied by CRP. The SII itself was calculated as the platelet count multiplied by the neutrophil count divided by the lymphocyte count. Disease activity was assessed using the BASDAI, with a score of 4 or higher defined as high disease activity. This approach allowed the researchers to test the discriminatory power of these composite indices against a standard clinical measure of patient-reported disease severity.
The demographic and clinical characteristics of the study population revealed a median age of 44.00 years for the ankylosing spondylitis patients and 42.50 years for the control group, with no statistically significant difference between the two groups. Among the patients, 68.4% were male and 31.6% were female, a distribution that was statistically similar to the control group. HLA-B27 positivity, a genetic marker strongly associated with the disease, was detected in 59.6% of the patients. The median body mass index in the patient group was 28.10 kg/m², and smoking was present in 52.6% of the participants. These baseline characteristics provide context for the subsequent analysis of inflammatory markers within this specific population.
Treatment modalities played a significant role in the study cohort, as the vast majority of patients were receiving long-term biologic therapy. The most frequently used biologic agents were golimumab, used by 36.0% of patients, and adalimumab, used by 25.4%. Other agents included certolizumab, etanercept, and secukinumab. The median duration of biologic therapy was 72 months, with an interquartile range of 36 to 96 months. This high proportion of patients on long-term biological treatment is a critical factor in interpreting the results, as these therapies are known to substantially suppress inflammatory markers, which may obscure differences between active and inactive disease groups.
The results showed that MII-1, MII-2, and MII-3 values were significantly higher in the ankylosing spondylitis patients compared to the healthy control group, with all p-values less than 0.001. This suggests that these composite indices possess the capacity to reflect systemic inflammation and can distinguish between individuals with the disease and those without. However, when the researchers compared the active and inactive disease groups based on BASDAI scores, no statistically significant differences were observed for any of the MII indices. The p-values for MII-1, MII-2, and MII-3 were 0.196, 0.134, and 0.176, respectively, indicating that these indices did not correlate with the current level of disease activity in this cohort.
Correlation analyses further clarified the relationship between these markers and clinical outcomes. No significant correlations were found between the MII indices, NLR, SII, or CRP and the BASFI or BASDAI scores, with all p-values greater than 0.05. The only exception was the platelet-to-lymphocyte ratio (PLR), which showed a weak but statistically significant positive correlation with the BASDAI score, with a correlation coefficient of 0.251 and a p-value of 0.007. This weak association suggests that PLR may provide a partial contribution to reflecting subjective disease activity, but it is not a strong predictor. Multivariable linear regression analyses, which adjusted for BMI, smoking status, HLA-B27 positivity, and duration of biologic therapy, confirmed that none of the MII indices emerged as independent predictors of BASDAI.
Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic performance of the inflammatory markers in distinguishing patients with ankylosing spondylitis from healthy controls. CRP demonstrated the highest diagnostic performance, with an area under the curve (AUC) of 0.746. Among the MII parameters, MII-2 and MII-3 showed comparable discriminative ability, both with an AUC of 0.714, while MII-1 showed moderate performance with an AUC of 0.699. In contrast, the individual hemogram-based indices of NLR, PLR, and SII failed to achieve significant discriminatory ability, with AUC values of 0.488, 0.491, and 0.557, respectively. This indicates that combining these ratios with CRP may enhance their diagnostic value compared to using them alone.
The authors discuss several limitations that affect the interpretation of the findings. The near-universal use of long-term biologic therapy is a major confounding factor, as these agents can normalize inflammatory biomarkers independently of actual disease activity. The assessment of disease activity was solely through the BASDAI, which is a patient-reported outcome measure that does not incorporate objective inflammatory parameters. The authors note that the Ankylosing Spondylitis Disease Activity Score (ASDAS), which includes CRP, would have been a more appropriate comparator for the MII indices. Additionally, the retrospective nature of the study meant that covariates such as BMI and smoking status were not available for the control group, preventing a multivariable logistic regression analysis for the diagnostic comparison between patients and controls.
The study concludes that the MII indices are not reliable indicators of disease activity status in the context of long-term biologic therapy for ankylosing spondylitis. While MII-2 and MII-3 demonstrated acceptable diagnostic performance in distinguishing patients from healthy controls, the clinical relevance of this finding is limited because the diagnosis of ankylosing spondylitis relies primarily on clinical and radiological criteria rather than inflammatory biomarkers alone. The lack of association between the MII indices and disease activity suggests that these composite biomarkers may have limited value in monitoring treatment response or disease progression in patients already on effective biologic therapy.
These findings highlight the complexity of using composite inflammatory indices in rheumatological diseases where treatment significantly alters the inflammatory profile. The study provides evidence that while these indices can identify the presence of systemic inflammation, they may not be sensitive enough to detect changes in disease activity in a treated population. Future research should focus on prospective studies with larger cohorts, including treatment-naïve patients, to better evaluate the utility of these indices. The authors emphasize the need for validation in diverse populations and the incorporation of objective disease activity scores to provide a more comprehensive assessment of the role of MII indices in clinical practice.
Subject of Research: Evaluation of Multi-Inflammatory Indices for disease activity assessment in ankylosing spondylitis
Article Title: New multi-inflammatory indices for evaluating disease activity in ankylosing spondylitis
Article References: Samanci, R., & Ataoglu, S. (2026). New multi-inflammatory indices for evaluating disease activity in ankylosing spondylitis. Egyptian Rheumatology and Rehabilitation, 53(1), Article 60. https://doi.org/10.1186/s43166-026-00428-7
Image Credits: AI Generated
DOI: 10.1186/s43166-026-00428-7
Keywords: Ankylosing Spondylitis, Multi-Inflammatory Index, Disease Activity, Inflammatory Markers, Rheumatology, CRP, BASDAI, Biologic Therapy, Cross-sectional Study, Diagnostic Performance, multi-inflammatory, indices
News Source: Ophelia Keating. (November 10, 2026). New Inflammatory Indices Fail to Track Ankylosing Spondylitis Activity. Scienmag.



